The much-awaited IPO of Anthem Biosciences Ltd., a Bengaluru-based contract research, development, and manufacturing organization (CRDMO), has hit a major milestone today. As of July 17, 2025, the basis of allotment for the ₹3,395 crore offer-for-sale (OFS) has been finalized, and investors can now check their allotment status through KFin Technologies, the official IPO registrar.
Anthem Biosciences IPO Allotment Status: Here’s How to Check
Investors can verify their share allotment through multiple platforms:
KFin Technologies (Registrar):
- Visit https://ris.kfintech.com/ipostatus/
- Select “Anthem Biosciences” from the dropdown
- Enter PAN, Application Number, DP/Client ID or Bank Account Number
- Submit CAPTCHA to view allotment status
BSE / NSE websites:
- Visit the IPO status section
- Enter PAN and/or Application number
- Select equity segment and submit
Broker/Demat Account:
- Check demat account linked to your application
- Allotted shares will be credited directly
- Refunds for non-allottees will begin July 18
With allotment confirmed today, anticipation is building among subscribers, especially after a remarkable oversubscription during the bidding window.
Anthem Biosciences IPO Demand Recap & Allotment Breakdown
The IPO, open from July 14 to July 16, saw overwhelming investor demand, being subscribed 63.86× overall:
- Qualified Institutional Buyers (QIBs): ~192×
- Non-Institutional Investors (NIIs): ~42×
- Retail Investors: ~5.6×
This strong response highlights high investor confidence in Anthem’s business fundamentals and future prospects. Based on the final allotment data:
- Retail applicants: 1 in 4 received 26 shares
- Small HNIs: 1 in 29 got 364 shares
- Big HNIs: 1 in 10 allotted 364 shares
This uneven allotment ratio reflects the intense competition, especially among institutional and HNI segments.
Price Band & Grey Market Buzz
The IPO was priced in the range of ₹540–₹570 per share. In the grey market, the Grey Market Premium (GMP) has been trending between ₹138 and ₹158, pointing to a likely listing price of ₹708–₹724 — an estimated premium of 25–30%.
Such bullish sentiment in the unofficial market is fueling optimism around the stock’s potential debut performance on July 21, 2025, when it will be listed on both BSE and NSE.
KFin Technologies has been instrumental in ensuring a smooth IPO process, including allotment handling, investor communication, and refund management.
Anthem Biosciences: Company Snapshot & Market Sentiment
Founded in 2006, Anthem Biosciences is a prominent CRDMO providing drug discovery, development, and fermentation-based API production services. The company’s FY25 performance further underscores its industry standing:
- Revenue: ₹1,930 crore
- Net Profit: ₹451 crore (YoY growth of 23%)
- EBITDA Margin: ~36.8%
With operations spanning 44 countries and a clientele of over 675, Anthem serves across biologics, peptides, biosimilars, enzymes, and nutritional actives. Its R&D-driven model is protected by 8 granted and 17 pending patents.
Market analysts have praised its integrated service model, tech adoption in advanced therapeutics like ADCs and RNAi, and its impressive financials. However, some have flagged valuation concerns:
- IPO Valuation: ~47.4× TTM EV/EBITDA
- Peer Average: ~42.7×
While the IPO is priced at a premium, its growth potential and profitability metrics are expected to justify investor interest, especially if it delivers consistent post-listing performance.
Conclusion:
The Anthem Biosciences IPO has stirred considerable enthusiasm in the market, underlined by oversubscription across categories and strong grey market cues. With allotment finalized today, investors can now verify their status through KFinTech, BSE, NSE, or their brokerage platforms.
As the company prepares to debut on July 21, market watchers will be closely monitoring if this high-potential CRDMO matches or exceeds listing expectations. For now, all eyes are on whether Anthem’s promising fundamentals translate into listing-day success — and a robust long-term bet in the fast-evolving global biotech outsourcing space.
F.A.Q.
– When was the IPO allotment finalized, and how can investors check their status?
The basis of allotment for the Anthem Biosciences IPO was finalized on July 17, 2025. Investors can check their allotment status by visiting the KFin Technologies IPO status page at ris.kfintech.com/ipostatus, selecting “Anthem Biosciences” from the dropdown, and entering their PAN, application number, or DP/Client ID. Allotment status can also be verified on the BSE and NSE websites or via one’s demat/brokerage platform.
– When will shares be credited or refunds processed?
Investors who were allotted shares will receive them in their demat accounts by July 18, 2025. Those who did not receive an allotment can expect refunds to begin processing on the same day. Refunds will be credited to the bank account used during the IPO application process.
– What does the grey market premium (GMP) suggest about the listing price?
As of July 17, the grey market premium (GMP) for Anthem Biosciences shares ranges between ₹144 and ₹156. Given the issue price of ₹570, the expected listing price is projected to be around ₹714 to ₹726, reflecting a possible 25% to 30% premium. This signals positive sentiment ahead of the official listing.
– When will Anthem Biosciences shares be listed, and what’s the market outlook?
The shares are scheduled to list on both the BSE and NSE on July 21, 2025. Market analysts expect a strong debut backed by solid financials, robust CRDMO sector demand, and Anthem’s leadership in drug research and manufacturing. However, actual listing performance may also depend on broader market trends and investor sentiment on the listing day.
Also read:-